Publishes Market Analysis of its Try & Tell Survey That Predicts Strong Ongoing Sales
FREDERICK, MD, USA, August 18, 2015 — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today published on its second quarter financial results along with a market analysis of its long term follow up surveys of customers who are managing pain with ActiPatch Therapy.
The Most Innovative Treatment for Chronic Pain FREDERICK, MD. August 10, 2015 — BioElectronics Corporation (OTC Pink: BIEL), maker of consumer medical electronics products for pain management, announced the filing of a 510(k) Premarket Notification for ActiPatch® Therapy with the U.S. Food and Drug Administration. The market clearance request is for the adjunctive treatment of … Continue Reading
FREDERICK, MD, USA, August 4, 2015 — BioElectronics Corporation (OTC Pink: BIEL), the maker of drug-free over-the-counter ActiPatch® Musculoskeletal Pain Therapy medical devices, announced today that its registry study of 44,000 users of its ActiPatch 7-day trial device has been published in the prominent peer reviewed medical journal Pain Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35. More than 5,000 chronic … Continue Reading
Topics will Include UK Progress and New Clinical Publications FREDERICK, MD. August 3, 2015 — BioElectronics Corporation (OTC Pink: BIEL), maker of consumer medical electronics products for pain management announced that Andrew J. Whelan, President will be interviewed by Stu Taylor on his program “On Business“ at 9am EST on Wednesday, August 5th. Listen to … Continue Reading
Appoints Market Leader, Medikon, LTD as distributor in Turkey FREDERICK, MD, USA, March 23, 2015 — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced medical devices, announced today that it has signed Medikon, one of the country’s leading medical suppliers as the distributor for RecoveryRx® Therapy for post-operative and chronic wound care, ActiPatch® Musculoskeletal … Continue Reading
FREDERICK, MD, USA, February 9, 2015 — BioElectronics Corporation (OTC: BIEL), the maker of an industry leading family of bioelectric pain therapy devices, said today that its Executive Vice President, Dr. Deepak Kotak, was interviewed by CEOLIVE.TV as part of its Executive Interview Series. The entire interview is available at http://ceolive.tv/bioelectronics/biel-videos/2515-ceolive-tv-interview-dr-deepak-kotak-vp-of-bioelectronics-corp-biel In the interview, Dr. … Continue Reading
FREDERICK, MD, USA, February 4, 2015– BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today released analysis of its ongoing and second long term follow up survey of customers in the United Kingdom and Ireland who are managing chronic pain with ActiPatch® Therapy, and reducing their dependence on systemic pain … Continue Reading
BioElectronics Corporation, USA, today announced that B. Braun Medical Ltd is the exclusive UK distributor of the BioElectronic’s RecoveryRx® pain device in orthopaedics and trauma. RecoveryRx® is a micro medical device that treats acute and chronic musculoskeletal pain and decreases oedema. RecoveryRx® will be introduced in the B. Braun enhanced recovery surgical programs, particularly hip … Continue Reading
FREDERICK, MD, USA, November 26, 2014 — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer and healthcare medical devices announced today that Pifflers United Chronic and Invisible Illnesses Support Community, www.facebook.com/PifflersUnited, is petitioning the United Kingdom’s NHS’ National Institute for Health & Care Excellence (NICE) for new guidelines for effective Fibromyalgia pain management … Continue Reading
Devon, United Kingdom – Pifflers United Chronic and Invisible Illnesses Support Community, www.facebook.com/PifflersUnited announced the release of results of a study of ActiPatch®, a new bioelectronic pain therapy device, in the self-management of fibromyalgia pain. The results demonstrated that when used in the area of worst pain, very significant clinically meaningful pain reduction can be … Continue Reading